Shibani Datta

Shibani Datta is a Global Market Manager in Demand Generation at QIAGEN. She has received her education in the field of Genetics from Texas A&M University, where she studied the mechanisms of DNA replication and amplification in Tetrahymena thermophila. Prior to her marketing role, she has trained as a biotechnologist in the field of assay development, antibody generation, and humanization. She is passionate about communicating the value of molecular technologies for research and healthcare.

EHA 2018

Stop by the QIAGEN booth #1160 at the 23rd EHA Congress from June 14-17, 2018 at Stockholm, where we will be featuring our latest Sample to Insight solutions, from trusted molecular detection to clinical decision support.


2018 ASCO Annual Meeting

We’re excited to attend the American Society of Clinical Oncology (ASCO) Annual Meeting 2018 in Chicago. Learn more.




AMP Europe 2018

Watch Dr. Atil Bisgil from Cukurova University, Turkey talk about expanding to microbiome research with the GeneReader NGS System. He discusses the pressures faced in a laboratory focused on next generation sequencing and research, looking toward the future of high-throughput NGS testing and expanding to microbiome research with the GeneReader.  


Key findings from a product launch survey in the pharma industry

Today, patients want to know more about new treatment options as they come to market, and be more engaged in their treatment decisions, receive more personalized healthcare and, ultimately, feel confident that they’re receiving the best treatment. This means that launching new products in this evolving environment will require launch teams from pharmaceutical companies to… Read article →


Liquid biopsy to detect tumor DNA: The possibilities

An article published on WBUR’s CommonHealth blog opens a window into liquid biopsy, also referred to as blood biopsy, in its current and future state. The article discusses how this rapidly-evolving technology has the potential to transform the way we detect and treat cancer. The technology of liquid biopsy is rapidly evolving, but still has… Read article →


QIAGEN receives FDA clearance for first-ever JAK2 test for use in diagnosis of additional myeloproliferative neoplasms

Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines Hilden, Germany, and Germantown, Maryland, January 23, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the… Read article →


QIAGEN at NGS Bioinformatics Challenge in Germany

QIAGEN had the pleasure of taking part in an NGS Bioinformatics Challenge run by the German Society for Pathology on the 9th and 10th of November in Halle, Germany. Three commercial organizations were supplied with vcf files from twelve samples sequenced using Illumina MiSeq™ Systems and the IonTorrent platform at Erlangen, Cologne Berlin. The identity… Read article →